Natco Pharma Limited
Records under this name other than the patents Natco Pharma Limited holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 34 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,735,415 | Acid addition salts of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide Term ended Term ended Oct 18, 2025 · From the USPTO record | Term ended | Term ended Oct 18, 2025 | From the USPTO record |
| US 8,183,253 | Phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase Lapsed on the fee record Ended May 22, 2024 · From the USPTO record | Lapsed on the fee record | Ended May 22, 2024 | From the USPTO record |
| US 9,227,948 | Process for the preparation of 2-substituted-2-(6-(substituted)-7-methylbenzo[D][1,3]dioxol-4-yl)acetic acid derivatives Lapsed on the fee record Ended Jan 5, 2024 · From the USPTO record | Lapsed on the fee record | Ended Jan 5, 2024 | From the USPTO record |
| US 10,383,872 | Pharmaceutical compositions comprising phenylaminopyrimidine derivative Lapsed on the fee record Ended Aug 20, 2023 · From the USPTO record | Lapsed on the fee record | Ended Aug 20, 2023 | From the USPTO record |
| US 7,910,598 | Phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase Lapsed on the fee record Ended Mar 22, 2023 · From the USPTO record | Lapsed on the fee record | Ended Mar 22, 2023 | From the USPTO record |
| US 10,047,088 | 1H-1,8-naphthyridin-2-ones as anti proliferative compounds Lapsed on the fee record Ended Aug 14, 2022 · From the USPTO record | Lapsed on the fee record | Ended Aug 14, 2022 | From the USPTO record |
| US 9,895,367 | Formulation comprising phenylaminopyrimidine derivative as active agent Lapsed on the fee record Ended Feb 20, 2022 · From the USPTO record | Lapsed on the fee record | Ended Feb 20, 2022 | From the USPTO record |
| US 9,765,072 | 1H-1,8-naphthyridin-2ones as anti proliferative compounds Lapsed on the fee record Ended Sep 19, 2021 · From the USPTO record | Lapsed on the fee record | Ended Sep 19, 2021 | From the USPTO record |
| US 8,067,422 | Crystal form of phenylamino pyrimidine derivatives Lapsed on the fee record Ended Nov 29, 2019 · From the USPTO record | Lapsed on the fee record | Ended Nov 29, 2019 | From the USPTO record |
| US 7,960,545 | Process for the prepartion of erlotinib Lapsed on the fee record Ended Jun 14, 2019 · From the USPTO record | Lapsed on the fee record | Ended Jun 14, 2019 | From the USPTO record |